echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JCO: Quality of life for prostate cancer patients treated with docetaxel vs. abiraterone

    JCO: Quality of life for prostate cancer patients treated with docetaxel vs. abiraterone

    • Last Update: 2021-12-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Docetaxel and abiraterone acetate in combination with prednisone or prednisone (AAP) can improve the survival rate of patients with locally advanced or metastatic hormone-sensitive prostate cancer when started together with standard care (SOC) androgen deprivation therapy


    In the STAMPEDE trial, a group of patients were enrolled at the same time and randomly received docetaxel + SOC or AAP + SOC


    Changes in overall QOL scores of patients in the two treatment groups

    Changes in overall QOL scores of patients in the two treatment groups

    A total of 515 patients were included: 173 received docetaxel + SOC, and 342 received AAP + SOC


    In the two years of randomization, the average modeled overall QOL score of patients receiving AAP+SOC treatment was 3.


    Compared with docetaxel + standard androgen deprivation therapy, patients with locally advanced or metastatic hormone-sensitive prostate cancer treated with abiraterone acetate combined with prednisone or prednisone + standard androgen deprivation therapy within two years Reported quality of life is better.


    Original source:

    Hannah L.


    Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.